Sarcoma & GIST
From the Journals
T-VEC plus pembrolizumab yields promising response rate in phase 2 sarcoma study
About one in three patients had a response, translating into the highest objective response rate seen in a study of unselected sarcoma patients...
News
FDA approves avapritinib for adults with GIST with PDGFRA mutation
Approval was based on an overall response rate of 84% among 43 adults with unresectable or metastatic gastrointestinal stromal tumors and PDGFRA...